metformin/pioglitazone vs ranolazine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of metformin/pioglitazone and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
( 7.3 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. 7.4 Drugs that Reduce Metformin Clearance Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical...
Actoplus Met
Ranexa
Actoplus Met is a drug that combines two medicines to help control blood sugar in adults with type 2 diabetes. It should be used with diet and exercise.
Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.
Actoplus Met helps lower blood sugar in adults who have type 2 diabetes. You should also follow a diet and exercise plan while taking this medicine. Actoplus Met is not for people with type 1 diabetes or diabetic ketoacidosis.
Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.
Actoplus Met contains pioglitazone and metformin. Pioglitazone makes your body more sensitive to insulin. Metformin reduces the amount of sugar your liver releases into your blood.
Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.
- • Upper respiratory infection
- • Swelling
- • Diarrhea
- • Headache
- • Weight gain
- • Dizziness
- • Headache
- • Constipation
- • Nausea
- Feeling sick to your stomach 21,946
- Loose or watery stools 21,887
- High blood sugar 18,329
- Feeling tired 17,252
- Sudden kidney damage 16,440
- Death 816
- Myocardial Infarction 640
- Chest Pain 605
- Angina Pectoris 594
- Stent Placement 582
Actoplus Met can cause or worsen heart failure in some people. Watch for signs like rapid weight gain, shortness of breath, and swelling. This medicine can also cause a rare but serious condition called lactic acidosis. Get medical help right away if you have symptoms like feeling very weak, muscle pain, trouble breathing, or stomach pain.
Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Actoplus Met will harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed.
It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.
How to Read This metformin/pioglitazone vs ranolazine Comparison
metformin/pioglitazone is classified in the Biguanide / TZD Combination drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, metformin/pioglitazone has 95,854 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to ranolazine blocks the pathways your kidneys use to get rid of metformin, which can cause metformin levels to rise too high. high levels of this drug increase the risk of a life-threatening acid imbalance.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for metformin/pioglitazone or ranolazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.